A study specifically examining FLS activity in RA showed that baricitinib abrogates IFNγ-induced invasiveness of FLS (68), which is of importance given their key contribution to pannus formation (aggressive cell masses that destroy articular cartilage and bone), one of the hallmarks of RA synovial pathobiology (81). This evidence concerns the gene IFNG and rheumatoid arthritis.